Document Detail


Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
MedLine Citation:
PMID:  6233003     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have utilized a human tumor cloning system to compare the antitumor activity of trimetrexate ( TMQ ), a new dihydrofolate reductase inhibitor, and ametantrone , a new anthracenedione, with that of analogs already in clinical trial (methotrexate and mitoxantrone). Sixty-nine of 136 tumors plated for the TMQ study and 84 of 228 tumors plated for the ametantrone study were evaluable for drug-sensitivity assays. The overall in vitro response rates (defined as a less than or equal to 50% survival of tumor colony-forming units) for TMQ were 20% and 23% at 0.1 and 1 microgram/ml, respectively; for ametantrone they were 13%, 21%, and 26% at 0.1, 1, and 10 micrograms/ml, respectively. The overall in vitro activity for both new compounds was similar to that of their clinically used analogs, but TMQ was active in eight of 47 methotrexate-resistant specimens and ametantrone in nine of 62 mitoxantrone-resistant specimens. A comparison of these in vitro results with the results of phase II clinical trials with both drugs should allow an evaluation of the utility of the human tumor cloning system for predicting clinical antitumor activity of analogs of currently available antineoplastic agents.
Authors:
B Lathan; D D Von Hoff; E Elslager
Related Documents :
1847123 - Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in h...
6332093 - Evaluation of various cytostatic drugs as local immunotherapeutic agents.
24435823 - Monitoring mammary tumor progression and effect of tamoxifen treatment in mmtv-pymt usi...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer treatment reports     Volume:  68     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1984 May 
Date Detail:
Created Date:  1984-06-29     Completed Date:  1984-06-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  733-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anthraquinones / therapeutic use*
Antineoplastic Agents / therapeutic use*
Cell Line
Colony-Forming Units Assay*
Drug Evaluation, Preclinical
Humans
Methotrexate / analogs & derivatives*
Mitoxantrone
Neoplasms / drug therapy
Quinazolines / therapeutic use*
Trimetrexate
Tumor Stem Cell Assay*
Chemical
Reg. No./Substance:
0/Anthraquinones; 0/Antineoplastic Agents; 0/Quinazolines; 52128-35-5/Trimetrexate; 59-05-2/Methotrexate; 64862-96-0/ametantrone; 65271-80-9/Mitoxantrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat.
Next Document:  Amplified pulmonary metastases of a rat rhabdomyosarcoma in response to nitrosourea treatment.